CIK: 0001646343
Total reported value
$120.1M
Reporting period: 2019-06-30 · Number of holdings: 23
NEXTHERA CAPITAL LP disclosed 23 holdings in its latest 13F filing for the period ending 2019-06-30, with total reported value of $120.1M and a quarterly turnover rate of 108.4%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "N"
Nexthera Capital LP's disclosed holdings carry a Herfindahl concentration index of 0.063 — mathematically equivalent to about 16 equally-sized positions, close to its 23 actual disclosed holdings. Value is spread relatively evenly across the portfolio rather than concentrated in a handful of names.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.69), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 2.3 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 6% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add ICPTUSD
+1175.4% $10.8M
Add NBIX
+284.3% $5.7M
Add SRPT
+136.6% $5.1M
Trim BOLDEUR
+17.3% $1.4M
Trim G0177J108
-75.6% -$1.4M
Trim IMMU
+56.6% $840.0K
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ICPTUSD | Intercept Pharmaceuticals In | Stock-Other | 10.10% | +8.48% | +1175.44% | |
| 2 | INSM | Insmed INC | Stock-Healthcare | 10.04% | +0.01% | +65.60% | |
| 3 | BOLDEUR | Audentes Therapeutics INC | Stock-Other | 9.27% | -2.60% | +17.31% | |
| 4 | NBIX | Neurocrine Biosciences INC | Stock-Healthcare | 6.50% | +3.93% | +284.28% | |
| 5 | SRPT | Sarepta Therapeutics INC | Stock-Healthcare | 6.37% | +3.29% | +136.56% | |
| 6 | GBTUSD | Global Blood Therapeutics In | Stock-Other | 6.23% | +0.64% | +63.38% | |
| 7 | IMMU | Immunomedics INC | Stock-Other | 6.06% | -1.74% | +56.59% | |
| 8 | CHRS | Coherus Oncology INC | Stock-Other | 5.82% | +5.82% | NEW | |
| 9 | ASND | Ascendis Pharma A/S | Stock-Other | 5.78% | +5.78% | NEW | |
| 10 | PCRX | Pacira Biosciences INC | Stock-Other | 5.40% | +5.40% | NEW | |
| 11 | URGN | UroGen Pharma Ltd. | Stock-Other | 5.29% | -0.65% | +33.39% | |
| 12 | QURE | uniQure N.V. | Stock-Other | 3.90% | +1.09% | +54.34% | |
| 13 | ✓ | Amarin Corp PLC | Stock-Other | 3.72% | -0.03% | +54.88% | |
| 14 | ABBV | Abbvie INC | Stock-Healthcare | 3.19% | +3.19% | NEW | |
| 15 | BHVN | Biohaven Ltd. | Stock-Other | 3.14% | +3.14% | NEW | |
| 16 | ✓ | Mylan N V | Stock-Other | 1.63% | +1.63% | NEW | |
| 17 | ITCIEUR | Intra-cellular Therapies INC | Stock-Other | 1.55% | +1.55% | NEW | |
| 18 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 1.48% | +1.48% | NEW | |
| 19 | MDGL | Madrigal Pharmaceuticals INC | Stock-Healthcare | 1.35% | +0.83% | +346.78% | |
| 20 | DERMEUR | Dermira INC | Stock-Other | 1.10% | +1.10% | NEW | |
| 21 | GILD | Gilead Sciences INC | Stock-Healthcare | 1.05% | +1.05% | NEW | |
| 22 | ANAB | Anaptysbio INC | Stock-Other | 0.57% | +0.57% | NEW | |
| 23 | ✓ | Stock-Other | 0.47% | -1.96% | -75.57% |
Not enough priced holdings yet to compute performance
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2019-06-30 | 23 | $120.1M | 100 | |
| 2019-03-31 | 24 | $82.4M | 100 | |
| 2018-12-31 | 23 | $242.6M | 100 | |
| 2018-09-30 | 56 | $521.8M | 71 | |
| 2018-06-30 | 45 | $645.9M | 53 | |
| 2018-03-31 | 40 | $607.3M | 62 | |
| 2017-12-31 | 39 | $542.4M | 88 | |
| 2017-09-30 | 38 | $388.7M | 100 | |
| 2017-06-30 | 41 | $229.5M | 63 | |
| 2017-03-31 | 38 | $196.0M | 100 | |
| 2016-12-31 | 39 | $170.6M | 100 | |
| 2016-09-30 | 33 | $162.7M | 81 | |
| 2016-06-30 | 35 | $115.5M | 100 | |
| 2016-03-31 | 32 | $96.5M | 90 | |
| 2015-12-31 | 45 | $70.5M | 0 |
Nexthera Capital LP's most significant position changes for 2019-06-30: Sold out: Heron Therapeutics INC (HRTX); New buy: Coherus Oncology INC (CHRS); New buy: Ascendis Pharma A/S (ASND); New buy: Pacira Biosciences INC (PCRX); Sold out: Bausch Health Cos INC (BHC).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ICPTUSD | Intercept Pharmaceuticals In | +8.5% | +1175.44% | Add |
| 2 | NBIX | Neurocrine Biosciences INC | +3.9% | +284.28% | Add |
| 3 | SRPT | Sarepta Therapeutics INC | +3.3% | +136.56% | Add |
| 4 | QURE | uniQure N.V. | +1.1% | +54.34% | Add |
| 5 | MDGL | Madrigal Pharmaceuticals INC | +0.8% | +346.78% | Add |
| 6 | GBTUSD | Global Blood Therapeutics In | +0.6% | +63.38% | Add |
| 7 | INSM | Insmed INC | 0% | +65.60% | Add |
| 8 | ✓ | Amarin Corp PLC | 0% | +54.88% | Add |
| 9 | URGN | UroGen Pharma Ltd. | -0.7% | +33.39% | Add |
| 10 | IMMU | Immunomedics INC | -1.7% | +56.59% | Add |
| 11 | ✓ | -2% | -75.57% | Trim | |
| 12 | BOLDEUR | Audentes Therapeutics INC | -2.6% | +17.31% | Add |
| 13 | HRTX | Heron Therapeutics INC | — | EXIT | Sold out |
| 14 | CHRS | Coherus Oncology INC | — | NEW | New buy |
| 15 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 16 | PCRX | Pacira Biosciences INC | — | NEW | New buy |
| 17 | BHC | Bausch Health Cos INC | — | EXIT | Sold out |
| 18 | STMLEUR | Stemline Therapeutics INC | — | EXIT | Sold out |
| 19 | NVS | Novartis Ag-sponsored Adr | — | EXIT | Sold out |
| 20 | ABBV | Abbvie INC | — | NEW | New buy |
| 21 | BHVN | Biohaven Ltd. | — | NEW | New buy |
| 22 | CBAYUSD | Cymabay Therapeutics INC | — | EXIT | Sold out |
| 23 | EXEL | Exelixis INC | — | EXIT | Sold out |
| 24 | ✓ | Acorda Therapeutics INC | — | EXIT | Sold out |
| 25 | ✓ | Mylan N V | — | NEW | New buy |
| 26 | ITCIEUR | Intra-cellular Therapies INC | — | NEW | New buy |
| 27 | REGN | Regeneron Pharmaceuticals | — | NEW | New buy |
| 28 | DERMEUR | Dermira INC | — | NEW | New buy |
| 29 | GILD | Gilead Sciences INC | — | NEW | New buy |
| 30 | KNSA | Kiniksa Pharmaceuticals International, plc | — | EXIT | Sold out |
| 31 | CHMA | Chiasma INC | — | EXIT | Sold out |
| 32 | DCPHEUR | Deciphera Pharmaceuticals In | — | EXIT | Sold out |
| 33 | SG7 | Sage Therapeutics INC | — | EXIT | Sold out |
| 34 | BMRN | Biomarin Pharmaceutical INC | — | EXIT | Sold out |
| 35 | ANAB | Anaptysbio INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2019-06-30 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-15 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-14 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-14 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-15 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-13 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-16 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0002043964
Total reported value
$120.1M
7 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0002110807
Total reported value
$119.9M
36 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0002106948
Total reported value
$120.2M
79 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0000924223
Total reported value
$4.0B
35 stks
2019-03-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Neurocrine Biosciences INC
CIK 0001103887
Total reported value
$1.8B
52 stks
2026-03-31
1 of the top 5 holdings overlap, including Insmed INC
CIK 0001263508
Total reported value
$17.4B
84 stks
2026-03-31
1 of the top 5 holdings overlap, including Insmed INC